Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patientâs immune system against their own cancer from within. Tocagen is currently studying its lead product candidate, Toca 511 & Toca FC, in a Phase 3 clinical trial for the treatment of patients with recurrent high grade glioma (HGG), a type of brain cancer with limited treatment options. Toca 511 & Toca FC has been granted Breakthrough Therapy Designation for the treatment of patients with recurrent HGG by the FDA, and PRIME (PRIority MEdicines) designation by the European Medicines Agency. Source
No articles found.
Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission...
Teligent is a specialty generic pharmaceutical ...
Healing Budz is a social healing platform created with the purpose of spreading kn...
Healing Budz is a social healing platform creat...
We at Auris Medical are dedicated to developing novel pharmaceutical products for ...
We at Auris Medical are dedicated to developing...
Progenics develops innovative medicines and other technologies to target and treat...
Progenics develops innovative medicines and oth...
Correvio has two marketed, in-hospital, cardiology products: BRINAVESSÂŽ (vernakal...
Correvio has two marketed, in-hospital, cardiol...
Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in th...
Nabriva Therapeutics is a commercial-stage biop...
Prevail Therapeutics is applying precision medicine to the development of gene the...
Prevail Therapeutics is applying precision medi...
Fibrocell is a cell and gene therapy company focused on improving the lives of peo...
Fibrocell is a cell and gene therapy company fo...
We are a vertically integrated, clinical stage gene therapy company with four ongo...
We are a vertically integrated, clinical stage ...
At Delee were fundamentally changing not only the way cancer is detected but also...
At Delee were fundamentally changing not only ...
Join the National Investor Network and get the latest information with your interests in mind.